Press Releases
Samsung Biologics’ Business Continuity Plan To Manage COVID-19 Situation
Samsung Biologics’ Business Continuity Plan To Manage COVID-19 Situation
In response to the Coronavirus (COVID-19) outbreak, Samsung Biologics has been taking proactive measures company-wide to ensure a safe working environment for our employees and continuous business operations for our clients.
As of the release of this statement, there are NO employees diagnosed with COVID-19 at Samsung Biologics. We have a fully dedicated task force in place to actively monitor and manage the situation around the clock should there be any case in the future.
We are also taking preventive measures against COVID-19 immediately to facilitate our full CGMP compliance, such as making efficient team shifts, deep-cleaning and disinfection of plant and business facilities according to WHO and KCDC guidelines, and implementing risk-control consultation from our on-site virus expert at Samsung Biologics.
Since the initial outbreak in late January, we have deployed our formal Business Continuity Plan (BCP) to protect our employees and maintain business operations against COVID-19, which includes:
a. Supply Chain Management: Our SCM team performed an assessment of the potential impact to our supply chain, and concluded that although some cargoes from US and China could be delayed due to flight cancelations, the COVID-19 situation does not pose any immediate threat to our raw material supply and to our vendors. Our team is actively monitoring this issue on a continuous basis and is taking all necessary steps to ensure the stable supply of critical raw materials for operations.
b. Business Continuity & Human Resource Management: Our Business Innovation team has deployed the Samsung Biologics BCP including an HR management guide for all employees to abide by. Under the BCP guidelines, measures i, ii, and iii below are being taken to provide a safe environment for our employees and visitors.
i) Corporate Monitoring of Employee/Visitor Health & Recent Travel History: Infrared thermal cameras have been installed at all entrances since late January, and steps were added to the visitor registration process to screen for anyone showing symptoms of COVID-19. A separate space has been reserved to isolate those showing potential symptoms. Also for visitors from high risk areas, restrictions have been implemented, including rescheduling nonessential meetings and audits. Furthermore a Company-wide survey is being conducted on an on-going basis to track employee/family member visits to regions with confirmed cases of COVID-19.
ii) Promotion of Hygiene Awareness and Individual Precautionary Measures: Banners and posters are prominently displayed throughout our site to encourage all employees to undertake independent precautionary and sanitary procedures including frequent hand washing and wearing masks in the office. Masks are distributed at the gate, and hand sanitizers and spray disinfectants are placed in the office areas and meeting rooms.
iii) Immediate Consultation with On-site Medical Staff & Virus Expert: We have a dedicated on-site virus expert and in-house medical staff to immediately respond to and provide oversight in the event of a suspected case. Also, COVID-19 prevention guides are being announced via our internal TV broadcast, web bulletin boards, and email newsletter. We are also keeping in close contact with government and key associated bodies to be notified of any developments as they occur so that we can react/respond promptly.
c. Strong CGMP Compliance and Quality System: At Samsung Biologics, we have strong GMP quality systems that effectively and strategically segregate the non-GMP and GMP operations to control any situation that would impact business operations. Procedures and equipment are already in place to mitigate potential contamination of supplies. From prompt individual testing for case clearance to company-wide cleaning work, we are meticulously screening for any exposure on a daily basis as part of COVID-19 risk management.
Samsung Biologics will continue to take preventative and responsive measures to protect our employees from the spread of COVID-19 at all times. Additionally, we are taking rigorous measures to proactively monitor, manage, and prevent any potential impact on CGMP operations and ensuring the safe and timely delivery of client products and services without interruption.
Samsung Biologics’ Business Continuity Plan To Manage COVID-19 Situation
In response to the Coronavirus (COVID-19) outbreak, Samsung Biologics has been taking proactive measures company-wide to ensure a safe working environment for our employees and continuous business operations for our clients.
As of the release of this statement, there are NO employees diagnosed with COVID-19 at Samsung Biologics. We have a fully dedicated task force in place to actively monitor and manage the situation around the clock should there be any case in the future.
We are also taking preventive measures against COVID-19 immediately to facilitate our full CGMP compliance, such as making efficient team shifts, deep-cleaning and disinfection of plant and business facilities according to WHO and KCDC guidelines, and implementing risk-control consultation from our on-site virus expert at Samsung Biologics.
Since the initial outbreak in late January, we have deployed our formal Business Continuity Plan (BCP) to protect our employees and maintain business operations against COVID-19, which includes:
a. Supply Chain Management: Our SCM team performed an assessment of the potential impact to our supply chain, and concluded that although some cargoes from US and China could be delayed due to flight cancelations, the COVID-19 situation does not pose any immediate threat to our raw material supply and to our vendors. Our team is actively monitoring this issue on a continuous basis and is taking all necessary steps to ensure the stable supply of critical raw materials for operations.
b. Business Continuity& Human Resource Management: Our Business Innovation team has deployed the Samsung Biologics BCP including an HR management guide for all employees to abide by. Under the BCP guidelines, measures i, ii, and iii below are being taken to provide a safe environment for our employees and visitors.
i) Corporate Monitoring of Employee/Visitor Health & Recent Travel History: Infrared thermal cameras have been installed at all entrances since late January, and steps were added to the visitor registration process to screen for anyone showing symptoms of COVID-19. A separate space has been reserved to isolate those showing potential symptoms. Also for visitors from high risk areas, restrictions have been implemented, including rescheduling nonessential meetings and audits. Furthermore a Company-wide survey is being conducted on an on-going basis to track employee/family member visits to regions with confirmed cases of COVID-19.
ii) Promotion of Hygiene Awareness and Individual Precautionary Measures: Banners and posters are prominently displayed throughout our site to encourage all employees to undertake independent precautionary and sanitary procedures including frequent hand washing and wearing masks in the office. Masks are distributed at the gate, and hand sanitizers and spray disinfectants are placed in the office areas and meeting rooms.
iii) Immediate Consultation with On-site Medical Staff & Virus Expert: We have a dedicated on-site virus expert and in-house medical staff to immediately respond to and provide oversight in the event of a suspected case. Also, COVID-19 prevention guides are being announced via our internal TV broadcast, web bulletin boards, and email newsletter. We are also keeping in close contact with government and key associated bodies to be notified of any developments as they occur so that we can react/respond promptly.
c. Strong CGMP Compliance and Quality System: At Samsung Biologics, we have strong GMP quality systems that effectively and strategically segregate the non-GMP and GMP operations to control any situation that would impact business operations. Procedures and equipment are already in place to mitigate potential contamination of supplies. From prompt individual testing for case clearance to company-wide cleaning work, we are meticulously screening for any exposure on a daily basis as part of COVID-19 risk management.
Samsung Biologics will continue to take preventative and responsive measures to protect our employees from the spread of COVID-19 at all times. Additionally, we are taking rigorous measures to proactively monitor, manage, and prevent any potential impact on CGMP operations and ensuring the safe and timely delivery of client products and services without interruption.